Novel renal injury markers in dogs with ehrlichiosis

PLoS One. 2023 Dec 14;18(12):e0293545. doi: 10.1371/journal.pone.0293545. eCollection 2023.

Abstract

Canine monocytic ehrlichiosis (CME) has been observed to impact renal function. Currently, the recognition of acute kidney injury is through the nonspecific biomarker serum creatinine (sCr). Novel markers of renal injury such as urinary clusterin (uClust) and urinary cystatin B (uCysB) may increase our understanding of the relationship between ehrlichiosis and renal cellular injury. The aim of this study was to evaluate novel renal injury biomarkers in dogs with acute CME. Twenty healthy dogs were enrolled in the control group (CG), and 16 dogs naturally infected with Ehrlichia canis were included in the Ehrlichia Group (EG). All dogs were followed for 45 days. EG dogs were treated with doxycycline twice daily for the first 30 days. Urine and serum were collected at: 0, 0.5, 1, 15, 30, and 45 days after start of treatment. Urine concentrations of uClust and uCysB were determined using a research ELISA immunoassay. A linear mixed model was used to estimate population mean of renal injury markers with patient as the random effect, and day and treatment as fixed effects. EG was observed to have higher uClust values compared to CG (estimated population mean EG: 213 ng/dL vs. CG: 84 ng/dL, P < 0.001). EG was observed to have higher uCysB values compared to CG (estimated population mean EG: 248 ng/dL vs. CG: 38 ng/dL, P < 0.001). Increases in uCysB and uClust suggest the presence of renal injury and a possible mechanism for the observed predisposition to chronic kidney disease in dogs with ehrlichiosis.

MeSH terms

  • Animals
  • Biomarkers
  • Dog Diseases* / epidemiology
  • Dogs
  • Doxycycline / therapeutic use
  • Ehrlichia canis
  • Ehrlichiosis* / drug therapy
  • Ehrlichiosis* / veterinary
  • Humans
  • Kidney
  • Monocytes

Substances

  • Doxycycline
  • Biomarkers

Grants and funding

This work was funded by the São Paulo Research Foundation (FAPESP), grant #2018/13427-6, (A.N.V.L.S. was a beneficiary of a doctoral scholarship). FAPESP had no role in the design, analysis or writing this manuscript. IDEXX Laboratories Inc. has provided all laboratory analysis at no charge as support collaboration for the study.